Bradykinin

1. Overview

Bradykinin (BK) is an endogenous vasoactive nonapeptide and one of the most potent naturally occurring mediators of vasodilation, pain, and inflammation in the human body. It consists of nine amino acids with the sequence Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg (RPPGFSPFR), has a molecular weight of 1060.2 g/mol, and the molecular formula C50H73N15O11 [1][18]. Discovered in 1949 by Brazilian pharmacologists Mauricio Rocha e Silva, Wilson Teixeira Beraldo, and Gastao Rosenfeld, bradykinin derives its name from the Greek words "bradys" (slow) and "kinein" (to move), describing the slow, sustained contraction it produced in isolated guinea pig ileum preparations [1].

Bradykinin is generated within the kallikrein-kinin system (KKS), one of the oldest and most conserved proteolytic cascade systems in mammalian physiology. When tissue injury, inflammation, or contact activation of coagulation factor XII occurs, the serine protease plasma kallikrein cleaves high-molecular-weight kininogen (HMWK) to release bradykinin. Similarly, tissue kallikreins cleave low-molecular-weight kininogen (LMWK) to release kallidin (Lys-bradykinin), a decapeptide that is subsequently converted to bradykinin by aminopeptidases [2][20][25].

Bradykinin signals through two G protein-coupled receptors: the B2 receptor (B2R), which is constitutively expressed on endothelial cells, smooth muscle, sensory neurons, and many other tissues; and the B1 receptor (B1R), which is normally expressed at very low levels but is dramatically upregulated during inflammation and tissue injury [4]. The effects of bradykinin are remarkably short-lived in vivo, with a plasma half-life of only 15 to 30 seconds, owing primarily to rapid degradation by angiotensin-converting enzyme (ACE, also known as kininase II) [2][11].

The clinical importance of bradykinin extends far beyond its role as an endogenous mediator. ACE inhibitors, among the most widely prescribed cardiovascular drugs worldwide, exert a significant portion of their therapeutic benefit through bradykinin potentiation, while their most common side effects -- dry cough (5-35% of patients) and rare but serious angioedema -- are direct consequences of bradykinin accumulation [15][16]. The B2 receptor antagonist icatibant (Firazyr) is approved for treatment of acute hereditary angioedema (HAE) attacks [8], and the COVID-19 pandemic brought renewed attention to bradykinin through the "bradykinin storm" hypothesis of SARS-CoV-2 pulmonary pathology [10].

Molecular Weight

1060.2 g/mol

Sequence

Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg (RPPGFSPFR)

Peptide Length

9 amino acids (nonapeptide)

Molecular Formula

C50H73N15O11

Primary Receptors

Bradykinin B2 receptor (constitutive); B1 receptor (inducible)

Primary Degradation Enzyme

ACE / Kininase II

Plasma Half-Life

Approximately 15-30 seconds

Discovery

Rocha e Silva, Beraldo, Rosenfeld, 1949

Approved B2 Antagonist

Icatibant (Firazyr), approved 2011 for HAE

2. Discovery and Historical Context

The story of bradykinin begins in the 1940s at the Instituto Biologico in Sao Paulo, Brazil. Mauricio Rocha e Silva, a physician and pharmacologist who had been studying proteolytic enzymes since 1939, was investigating the mechanisms of circulatory shock -- then widely attributed to histamine release. In a pivotal experiment, Rocha e Silva incubated plasma globulins with venom from the Brazilian lancehead pit viper Bothrops jararaca and observed a powerful hypotensive response in dogs that could not be explained by histamine alone [1].

Working with his colleagues Wilson Teixeira Beraldo and Gastao Rosenfeld (the latter an expert in snake venom at the Butantan Institute), Rocha e Silva systematically characterized this new substance. They found that both trypsin and snake venom could liberate the active factor from plasma globulins, that it caused hypotension and smooth muscle contraction, and that its action was slow and sustained compared to histamine. Their 1949 paper in the American Journal of Physiology, titled "Bradykinin, a hypotensive and smooth muscle stimulating factor released from plasma globulin by snake venoms and by trypsin," introduced the name bradykinin and established the foundations of what would become the kallikrein-kinin system [1].

In 1960, Elliot and colleagues determined the complete amino acid sequence of bradykinin, confirming it as a nonapeptide (Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg) and enabling its chemical synthesis [18]. The identification of ACE as the primary bradykinin-degrading enzyme (kininase II) by Erdos and Sloane in 1962 proved to be a pivotal discovery that would later connect the kinin system to the renin-angiotensin system [11]. This connection gained profound clinical significance when David Cushman and Miguel Ondetti at Bristol-Myers Squibb developed captopril in the 1970s -- the first ACE inhibitor, inspired by bradykinin-potentiating factors found in the very same Bothrops jararaca venom that had led to bradykinin's discovery [3].

The cloning of the B2 receptor in 1991 and the B1 receptor in 1994 opened the modern era of kinin receptor pharmacology and drug development [4].

3. Pharmacokinetics

Plasma Half-Life and Degradation Kinetics

Bradykinin has one of the shortest plasma half-lives of any biologically active peptide: approximately 15 to 30 seconds under normal physiological conditions [2][11]. This ultrashort half-life reflects the extraordinary efficiency of the kininase system, particularly the abundance of ACE on pulmonary vascular endothelium. In a single pass through the pulmonary vasculature, approximately 80 to 95% of circulating bradykinin is degraded, making the lungs the most important site of systemic bradykinin clearance [2][11].

Degradation Pathways and Enzyme Contributions

Three major metalloproteinases constitute the primary kininase system, each contributing distinct proportions of total bradykinin degradation [2][11][12]:

ACE (Kininase II) -- 45-80% of total degradation: Angiotensin-converting enzyme is the principal enzyme responsible for bradykinin inactivation. ACE is a zinc metallopeptidase anchored to the surface of endothelial cells, particularly abundant in the lung vasculature. It cleaves the Pro7-Phe8 and Phe8-Arg9 bonds, generating inactive fragments. The ACE molecule contains two catalytic domains (N-domain and C-domain) that differ in their affinity for bradykinin. The C-domain is primarily responsible for bradykinin hydrolysis, while the N-domain plays a secondary role. Different ACE inhibitors show varying selectivity for these domains, which has clinical implications for the degree of bradykinin potentiation [12][13].

Aminopeptidase P (APP) -- 15-30% of total degradation: Cleaves the Arg1-Pro2 bond at the N-terminus. This pathway becomes relatively more important when ACE is inhibited. Genetic polymorphisms in APP (XPNPEP2 gene) that reduce enzyme activity have been associated with increased susceptibility to ACE inhibitor-induced angioedema, demonstrating the clinical importance of this secondary pathway [2][14].

Carboxypeptidase N/M (Kininase I) -- 5-15% of total degradation: Removes the C-terminal arginine (Arg9) from bradykinin to generate des-Arg9-bradykinin. While quantitatively minor, this pathway is physiologically significant because des-Arg9-bradykinin is the preferential agonist of the inducible B1 receptor. During inflammation, when B1R expression is upregulated, this metabolic pathway effectively converts an acute-phase mediator (B2R agonist) into a chronic-phase mediator (B1R agonist) [2][4].

Neutral endopeptidase (NEP/neprilysin) -- variable contribution: Also participates in bradykinin metabolism, particularly in tissues. The combination of an ACE inhibitor with a neprilysin inhibitor (as in sacubitril/valsartan) theoretically doubles the inhibition of bradykinin degradation, which is why sacubitril must never be combined with an ACE inhibitor (contraindicated due to severe angioedema risk) [14].

ACE Inhibitor Potentiation

In the presence of ACE inhibitors, the plasma half-life of bradykinin increases 5- to 12-fold (from approximately 15-30 seconds to 2-6 minutes), dramatically amplifying bradykinin's biological effects [12][16]. The degree of potentiation varies among ACE inhibitors based on their relative affinity for the C-domain vs. N-domain of ACE: inhibitors with stronger C-domain binding (where bradykinin is primarily degraded) produce greater bradykinin potentiation. This differential potentiation correlates with clinical observations -- some ACE inhibitors appear to have higher rates of cough and angioedema than others [13].

Tissue vs. Plasma Kinetics

Local tissue concentrations of bradykinin can be substantially higher than plasma levels, particularly at sites of inflammation where kallikrein activity is elevated and kininase activity may be saturated. Tissue bradykinin concentrations at inflammatory sites are estimated to reach 10 to 100 nM -- well above the EC50 for both B2R activation (approximately 1 nM) and nociceptor sensitization [6][7]. The discrepancy between extremely low plasma levels and high local tissue concentrations reflects bradykinin's role as a local mediator rather than a circulating hormone.

4. The Kallikrein-Kinin System

Bradykinin Biosynthesis

Bradykinin generation occurs through the kallikrein-kinin cascade, operating in both plasma and tissue compartments [2][20][25]:

Plasma pathway: Contact activation of coagulation factor XII (Hageman factor) on negatively charged surfaces (such as damaged endothelium, bacterial cell walls, or foreign materials) triggers the conversion of prekallikrein to plasma kallikrein. Active plasma kallikrein then cleaves high-molecular-weight kininogen (HMWK, 120 kDa) at specific sites to release bradykinin. This pathway is regulated by C1-esterase inhibitor (C1-INH), which inactivates both plasma kallikrein and factor XIIa [20][25].

Tissue pathway: Tissue kallikreins (encoded by the KLK gene family, particularly KLK1) preferentially cleave low-molecular-weight kininogen (LMWK, 68 kDa) to release kallidin (Lys-bradykinin), a decapeptide bearing an additional N-terminal lysine residue. Aminopeptidases then convert kallidin to bradykinin by removing the N-terminal lysine [2][17].

5. Mechanism of Action

B2 Receptor Signaling

The bradykinin B2 receptor (B2R, encoded by the BDKRB2 gene) is a 391-amino-acid G protein-coupled receptor constitutively expressed in endothelial cells, vascular smooth muscle, sensory neurons, fibroblasts, epithelial cells, and many other tissue types [4][5]. It is the principal mediator of bradykinin's acute physiological effects.

Upon bradykinin binding, B2R couples primarily to the heterotrimeric G protein Gq/11. The activated Gq alpha-subunit stimulates phospholipase C-beta (PLC-beta), which hydrolyzes membrane phosphatidylinositol 4,5-bisphosphate (PIP2) into two second messengers: inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 triggers calcium release from endoplasmic reticulum stores, elevating intracellular calcium concentration, while DAG activates protein kinase C (PKC) [4][5].

This core signaling cascade drives bradykinin's principal downstream effects:

• Nitric oxide (NO) release: Elevated intracellular calcium activates endothelial nitric oxide synthase (eNOS), producing NO that diffuses to underlying vascular smooth muscle to cause vasodilation via cyclic GMP signaling [15].
• Prostacyclin (PGI2) synthesis: Calcium-dependent activation of phospholipase A2 liberates arachidonic acid, which is converted to prostacyclin by cyclooxygenase and prostacyclin synthase, providing a second vasodilatory pathway [15].
• Endothelium-derived hyperpolarizing factor (EDHF): Bradykinin stimulates EDHF production, contributing to vasodilation particularly in resistance arteries [15].

Cryo-electron microscopy studies in 2021-2022 resolved the first high-resolution structures of human B1R and B2R receptors in complex with Gq proteins, revealing the molecular determinants of kinin binding and receptor activation [5][19]. These structures showed that bradykinin adopts a U-shaped conformation within the B2R orthosteric pocket, with both the N-terminal arginine and C-terminal arginine making critical contacts that stabilize the active receptor conformation.

Following agonist stimulation, B2R undergoes rapid desensitization through phosphorylation by G protein-coupled receptor kinases (GRKs) and subsequent beta-arrestin recruitment, leading to receptor internalization via clathrin-coated pits [4].

B1 Receptor Signaling

The bradykinin B1 receptor (B1R, encoded by BDKRB1) is structurally and pharmacologically distinct from B2R [4][19]. Under normal physiological conditions, B1R is expressed at very low levels in most tissues. However, its expression is dramatically upregulated (10- to 100-fold) by pro-inflammatory cytokines (IL-1-beta, TNF-alpha), bacterial lipopolysaccharide (LPS), tissue injury, and oxidative stress. This induction is mediated primarily through NF-kappa-B-dependent transcription [4][7].

The preferential endogenous agonist of B1R is des-Arg9-bradykinin (and des-Arg10-kallidin), the C-terminally truncated metabolites produced by kininase I (carboxypeptidase N/M) cleavage of bradykinin and kallidin, respectively. Intact bradykinin has minimal affinity for B1R [4][19].

B1R signals through similar Gq/PLC/calcium pathways as B2R but differs in several key respects: it does not undergo rapid desensitization or internalization, allowing for sustained signaling; and its inducible nature means it primarily operates during pathological states such as chronic inflammation, sepsis, and neuropathic pain [4][7].

Vasodilation

Bradykinin is one of the most potent endogenous vasodilators known. Acting through B2R on endothelial cells, it triggers the release of three principal vasodilatory mediators: nitric oxide, prostacyclin, and EDHF. These mediators act in concert on adjacent vascular smooth muscle cells to cause relaxation and reduce peripheral vascular resistance. The relative contribution of each pathway varies by vascular bed and vessel size [15][17].

Pain and Nociception

Bradykinin is among the most potent endogenous algogenic (pain-producing) substances, active at nanomolar concentrations. When released at sites of tissue damage or inflammation, it acts on B2 receptors on the peripheral terminals of nociceptive C-fibers and A-delta fibers [6][7].

The nociceptive signaling mechanism involves B2R-Gq-PLC activation in sensory neurons, leading to: (1) inhibition of M-type potassium channels (KCNQ/Kv7 family), reducing the hyperpolarizing influence that normally restrains neuronal excitability; (2) opening of calcium-activated chloride channels (TMEM16A), producing depolarization; and (3) sensitization of TRPV1 (transient receptor potential vanilloid 1) and TRPA1 channels through PKC-dependent phosphorylation, lowering their activation thresholds so that normally innocuous thermal and chemical stimuli become painful (hyperalgesia) [6][7].

During sustained inflammation, the upregulated B1 receptor contributes to ongoing pain signaling through des-Arg9-bradykinin, maintaining nociceptor sensitization even as B2R-mediated acute signaling is desensitized [7].

Vascular Permeability and Edema

Bradykinin is a key mediator of increased vascular permeability, particularly at postcapillary venules. B2R activation on endothelial cells triggers intracellular calcium elevation, leading to endothelial cell contraction, disruption of intercellular tight junctions, and formation of inter-endothelial gaps through which plasma proteins and fluid extravasate into the interstitial space [14][24]. Additionally, bradykinin promotes transcellular fluid transport independent of gap formation. These effects produce localized edema -- the hallmark of bradykinin-mediated angioedema -- and contribute to the inflammatory exudate at sites of tissue injury [24].

6. Dose-Response Relationships

Vascular Dose-Response

Bradykinin demonstrates potent, dose-dependent vasodilatory effects across multiple vascular beds. In human forearm plethysmography studies, intra-arterial bradykinin infusion produces dose-dependent increases in forearm blood flow with an ED50 of approximately 10 to 30 pmol/min and a maximal response at 100 to 300 pmol/min. The dose-response curve is steep, with a Hill coefficient of approximately 1.5, reflecting cooperative receptor activation and amplification through the NO-cGMP cascade [15][17].

Nociceptive Dose-Response

Intradermal bradykinin injection in human volunteers produces dose-dependent pain responses:

• 1 to 10 nM: Subthreshold, no pain
• 10 to 100 nM: Mild to moderate pain with sensitization of surrounding tissue
• 100 nM to 1 mcM: Significant pain with hyperalgesia and allodynia in surrounding skin
• Above 1 mcM: Near-maximal pain response with pronounced flare and edema

The dose-response curve for bradykinin-induced pain is shifted leftward (potentiated) in inflamed tissue, where B1R upregulation and prostaglandin release lower nociceptor thresholds [6][7].

ACE Inhibitor Dose-Dependent Potentiation

The clinical effects of bradykinin potentiation by ACE inhibitors follow a dose-response pattern relevant to both therapeutic benefit and adverse effects:

• Cardioprotection: Bradykinin-mediated NO release increases proportionally with ACE inhibitor dose up to the recommended therapeutic range, contributing to the full cardiovascular benefit
• Cough incidence: ACE inhibitor-induced cough follows a relatively flat dose-response, occurring at similar frequency across a wide dose range, suggesting a threshold effect rather than a graded dose-response [16]
• Angioedema risk: The incidence of ACE inhibitor-induced angioedema (0.1-0.7%) does not clearly increase with dose, indicating that susceptibility depends more on individual variation in alternative kininase pathways (APP, DPP-IV) than on the degree of ACE inhibition [14]

7. Researched Applications and Clinical Relevance

ACE Inhibitor Pharmacology: Cardioprotection and Adverse Effects

Evidence level: Strong (decades of clinical and mechanistic research)

The most clinically significant aspect of bradykinin biology is its central role in ACE inhibitor pharmacology. ACE (kininase II) sits at the intersection of two opposing vasoactive pathways: it converts angiotensin I to the vasoconstrictor angiotensin II, and simultaneously degrades the vasodilator bradykinin. ACE inhibitors therefore have a dual mechanism -- reducing angiotensin II while potentiating bradykinin [12][13][15].

Cardioprotection: Bradykinin potentiation contributes significantly to the cardiovascular benefits of ACE inhibitors beyond what can be explained by angiotensin II suppression alone. Through B2R activation, accumulated bradykinin stimulates endothelial NO and prostacyclin release, improving endothelial function, reducing oxidative stress, inhibiting smooth muscle proliferation, and providing antithrombotic effects. Animal studies have demonstrated that the cardioprotective effects of ACE inhibitors can be abolished by B2R antagonists or NOS inhibitors, confirming the essential role of the bradykinin-NO pathway [15].

ACE inhibitor-induced cough: Dry, persistent cough occurs in 5-35% of patients taking ACE inhibitors, with higher incidence in women and individuals of East Asian descent. The mechanism involves bradykinin and substance P accumulation in the bronchial mucosa (both peptides are ACE substrates), stimulating prostaglandin E2 synthesis and sensitizing airway cough receptors via C-fiber activation [16]. Genetic polymorphisms in the B2R gene (BDKRB2) have been associated with susceptibility to ACE inhibitor cough [16].

ACE inhibitor-induced angioedema: This rare (0.1-0.7% incidence) but potentially life-threatening adverse effect involves bradykinin-mediated subcutaneous and submucosal edema, typically affecting the face, lips, tongue, and larynx. Unlike histamine-mediated angioedema, it does not respond to antihistamines, corticosteroids, or epinephrine, and may require specific bradykinin-targeted therapy [14][24]. Approximately half of affected patients demonstrate impaired bradykinin degradation through alternative pathways (aminopeptidase P, dipeptidyl peptidase IV), creating a "perfect storm" of kinin excess when ACE is inhibited [14][24].

Hereditary Angioedema

Evidence level: Strong (FDA-approved therapies)

Hereditary angioedema (HAE) is an autosomal dominant disorder, most commonly caused by C1-esterase inhibitor (C1-INH) deficiency (type I) or dysfunction (type II). C1-INH normally regulates both plasma kallikrein and factor XIIa, the two key activators of the contact pathway. When C1-INH is deficient, uncontrolled kallikrein activity generates excessive bradykinin from HMWK, producing recurrent episodes of nonpruritic, non-pitting subcutaneous and submucosal edema that can affect the face, extremities, genitalia, gastrointestinal tract, and -- most dangerously -- the upper airway [8][20][25].

Icatibant (Firazyr): This synthetic decapeptide is a selective, competitive B2 receptor antagonist approved (FDA 2011, EMA 2008) for the treatment of acute HAE attacks in adults. It is administered as a 30 mg subcutaneous injection in the abdominal area, with onset of symptom relief typically within 30 minutes and median time to 50% symptom reduction of approximately 2 hours. Additional doses may be given at intervals of at least 6 hours if needed, up to a maximum of 3 doses in 24 hours. Icatibant has approximately 97% bioavailability and a terminal half-life of 1 to 2 hours. The most common adverse effect is injection site reactions (97% of patients) [8][23].

Lanadelumab (Takhzyro): A fully human monoclonal antibody targeting plasma kallikrein, approved for prophylaxis of HAE attacks. Administered as 300 mg subcutaneously every 2 weeks (or every 4 weeks in well-controlled patients), lanadelumab reduced HAE attack rates by 87% versus placebo in the Phase III HELP trial [9].

Berotralstat (Orladeyo): An oral, once-daily small-molecule plasma kallikrein inhibitor approved for HAE prophylaxis, providing a non-injectable alternative. It binds within the active site of plasma kallikrein, while lanadelumab blocks substrate access by binding the enzyme surface [9].

C1-INH replacement: Plasma-derived (Berinert, Cinryze) and recombinant (Ruconest) C1-INH concentrates address the underlying deficiency directly and are used for both acute treatment and prophylaxis [20].

New HAE Therapies Approved in 2025

The HAE therapeutic landscape expanded dramatically in 2025 with three new FDA approvals within a three-month period:

Garadacimab (Andembry, CSL Behring): Approved June 2025, garadacimab is the first therapy to target activated factor XII (FXIIa), the initiating factor of the contact activation cascade that drives bradykinin generation. Administered as a once-monthly subcutaneous injection, it reduced HAE attack frequency by 87% versus placebo in the Phase 3 VANGUARD trial. By targeting the most upstream component of the bradykinin-generating cascade, garadacimab offers a mechanistically distinct approach from kallikrein inhibitors and B2R antagonists.

Sebetralstat (Ekterly): Approved July 2025, sebetralstat is the first oral on-demand treatment for acute HAE attacks. As an oral plasma kallikrein inhibitor taken at attack onset, it provides a patient-friendly alternative to injectable icatibant for acute treatment.

Donidalorsen (Dawnzera, Ionis/Otsuka): Approved August 2025, donidalorsen is the first RNA-targeted prophylactic therapy for HAE. This antisense oligonucleotide reduces hepatic production of prekallikrein (PKK), the precursor to plasma kallikrein, thereby reducing bradykinin generation at the source. Dosed every 4 to 8 weeks subcutaneously, the Phase 3 OASIS-HAE study demonstrated an 81% reduction in HAE attacks with 4-week dosing, increasing to 87% from the second dose. By lowering PKK protein levels rather than inhibiting the active enzyme, donidalorsen represents a fundamentally different pharmacological strategy within the kallikrein-kinin system.

Pain and Inflammation

Evidence level: Strong (extensive preclinical; pharmacological validation)

Bradykinin is one of the most potent endogenous pain mediators and a key driver of the inflammatory response. At sites of tissue injury, kallikrein activation generates bradykinin that produces acute pain through direct nociceptor activation and sensitization, while simultaneously driving the cardinal signs of inflammation -- redness (vasodilation), heat, swelling (increased vascular permeability), and pain [6][7].

The dual receptor system provides temporal organization to bradykinin's inflammatory role: B2R mediates the acute phase (first minutes to hours), while B1R upregulation during sustained inflammation maintains signaling during the chronic phase. B1R-directed therapeutic strategies remain under investigation for chronic inflammatory pain, neuropathic pain, and conditions such as diabetic neuropathy [7].

Despite the clear role of bradykinin in pain pathophysiology, development of bradykinin receptor antagonists as analgesics has not achieved clinical success comparable to that seen in angioedema. This may reflect the redundancy of pain signaling pathways, where multiple inflammatory mediators (prostaglandins, substance P, CGRP, nerve growth factor) operate in parallel [6][7].

Cardiovascular Protection

Evidence level: Strong (clinical outcomes data from ACE inhibitor trials)

The bradykinin-nitric oxide-prostacyclin axis is now recognized as a critical component of cardiovascular homeostasis. Bradykinin, acting through endothelial B2R, contributes to basal vascular tone, flow-mediated vasodilation, and endothelial integrity [15][17].

The cardioprotective role of bradykinin is supported by multiple lines of evidence: ACE inhibitors reduce cardiovascular mortality beyond what ARBs (angiotensin receptor blockers) achieve at equivalent angiotensin II suppression, and this "additional benefit" is attributable to bradykinin potentiation; bradykinin preconditioning protects the myocardium against ischemia-reperfusion injury; and B2R knockout animals show accelerated endothelial dysfunction and increased thrombotic tendency [15][17].

COVID-19 Bradykinin Storm Hypothesis

Evidence level: Moderate (computational analysis and supportive experimental data)

In July 2020, a team led by Daniel Jacobson at Oak Ridge National Laboratory published a landmark computational analysis in eLife using the Summit supercomputer to analyze gene expression data from bronchoalveolar lavage fluid of COVID-19 patients [10]. Their analysis revealed dramatic dysregulation of the renin-angiotensin and kallikrein-kinin systems in SARS-CoV-2-infected lungs.

The key findings were: SARS-CoV-2 downregulates ACE expression while upregulating ACE2, bradykinin receptors (both B1R and B2R), and kallikrein enzymes. This would simultaneously reduce bradykinin degradation and increase both bradykinin production and receptor sensitivity, creating a "bradykinin storm" [10]. The hypothesis provided a mechanistic explanation for the severe pulmonary edema, hyaluronic acid accumulation (forming a hydrogel in alveoli), and multi-organ involvement seen in severe COVID-19 [10][21].

Subsequent experimental work supported the hypothesis: the SARS-CoV-2 main protease (3CLpro) was shown to cleave NEMO (NF-kappa-B Essential Modulator), dysregulating NF-kappa-B signaling in ways that could contribute to kinin storm. This work also suggested that existing drugs targeting the bradykinin pathway -- including icatibant and kallikrein inhibitors -- could have therapeutic potential in severe COVID-19 [10][21].

8. Clinical Evidence Summary

9. Comparative Effectiveness: Bradykinin vs. Kallidin vs. des-Arg9-Bradykinin

Bradykinin vs. Kallidin (Lys-Bradykinin)

Kallidin is a decapeptide (Lys-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg) with an additional N-terminal lysine residue. While bradykinin is primarily released from HMWK by plasma kallikrein, kallidin is released from LMWK by tissue kallikreins (particularly KLK1). Both peptides are full agonists at B2R, though kallidin shows slightly lower potency than bradykinin in most bioassays. Kallidin is readily converted to bradykinin by plasma aminopeptidases, and its C-terminal truncation by kininase I produces des-Arg10-kallidin, the most potent endogenous B1R agonist [2][4][18].

Key comparative differences:

• Source: Bradykinin is primarily a product of the plasma contact activation pathway (relevant to HAE); kallidin is primarily a product of the tissue kallikrein pathway (relevant to local inflammatory responses)
• Potency at B2R: Bradykinin is approximately 2- to 5-fold more potent than kallidin for B2R-mediated vasodilation and permeability in most vascular beds
• Metabolic fate: Both are degraded by ACE and accumulate during ACE inhibitor therapy; however, kallidin is additionally subject to aminopeptidase-mediated conversion to bradykinin
• B1R metabolites: des-Arg10-kallidin (derived from kallidin) is approximately 10-fold more potent at B1R than des-Arg9-bradykinin (derived from bradykinin), making it the most potent endogenous B1R agonist

des-Arg9-Bradykinin (B1 Agonist)

des-Arg9-bradykinin is the octapeptide (Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe) generated by carboxypeptidase N or M removal of the C-terminal arginine from bradykinin. It has negligible affinity for B2R but is the preferential endogenous agonist of B1R. In healthy tissues where B1R expression is minimal, des-Arg9-bradykinin is essentially inactive. However, during inflammation, infection, or tissue injury, the dramatic upregulation of B1R creates a substrate for des-Arg9-bradykinin to drive sustained inflammatory signaling, vascular permeability, and nociception [4][7][19].

Clinical relevance of the B2R-to-B1R metabolic switch: The kininase I-mediated conversion of bradykinin to des-Arg9-bradykinin represents a pharmacological "switch" from acute to chronic signaling. In the context of ACE inhibitor therapy, when bradykinin degradation by ACE is blocked, more bradykinin is available for kininase I processing to des-Arg9-bradykinin. If concurrent inflammation has upregulated B1R, this shunting can amplify chronic inflammatory and nociceptive signaling -- a mechanism proposed to contribute to ACE inhibitor-induced persistent cough in some patients [16].

Summary Table of Kinin Comparisons

| Feature | Bradykinin | Kallidin (Lys-BK) | des-Arg9-BK | |---|---|---|---| | Length | 9 amino acids | 10 amino acids | 8 amino acids | | Precursor | HMWK | LMWK | Bradykinin (via CPN/M) | | Releasing enzyme | Plasma kallikrein | Tissue kallikrein (KLK1) | N/A (metabolite) | | Primary receptor | B2R | B2R | B1R | | Receptor expression | Constitutive | Constitutive | Inducible (inflammation) | | Plasma half-life | 15-30 seconds | 15-30 seconds | 1-2 minutes (longer due to ACE resistance) | | Temporal role | Acute phase | Acute phase | Chronic / inflammatory phase | | Response to ACE inhibition | Accumulates (5-12x increase) | Accumulates | May increase (metabolic shunting) |

10. Safety Considerations

Bradykinin is an endogenous peptide with no therapeutic dosing regimen for direct human administration. Safety considerations are relevant in the context of pathological bradykinin excess and the use of drugs that modulate the kinin system.

Bradykinin excess states: Uncontrolled bradykinin generation or impaired degradation causes potentially life-threatening angioedema. Laryngeal edema in HAE carries an estimated mortality of 25-40% if untreated, and abdominal attacks can mimic surgical emergencies [8][20]. ACE inhibitor-associated angioedema, while rare, requires immediate recognition because it does not respond to standard allergy treatments (epinephrine, antihistamines, corticosteroids) [14][24].

Icatibant safety: Icatibant is generally well tolerated. Injection site reactions (erythema, swelling, burning) occur in approximately 97% of patients but are transient and self-limiting. Systemic adverse effects are uncommon and include pyrexia, transaminase elevation, dizziness, and rash. No serious drug-related adverse events were reported in pivotal trials. Because icatibant blocks B2R, there is a theoretical concern about transient loss of bradykinin-mediated cardiovascular protection, though no clinical consequences have been observed with intermittent acute dosing [8][23].

Kallikrein inhibitor safety: Lanadelumab and berotralstat have favorable safety profiles in long-term prophylaxis studies. Common adverse effects of lanadelumab include injection site reactions and headache. Berotralstat may cause gastrointestinal adverse effects (abdominal pain, vomiting, diarrhea) and mild facial skin reactions [9].

Drug interaction awareness: Patients taking ACE inhibitors are at increased risk for bradykinin-mediated events if they also use drugs that inhibit alternative bradykinin degradation pathways (e.g., DPP-IV inhibitors/gliptins, neprilysin inhibitors). The combination of sacubitril (neprilysin inhibitor) with ACE inhibitors is contraindicated due to the risk of severe angioedema [14].

Hypotension risk with exogenous bradykinin: In research settings where bradykinin is infused intra-arterially or intravenously, dose-dependent hypotension can occur. This is predictable from bradykinin's vasodilatory mechanism and is readily managed by stopping the infusion. The ultrashort half-life (15-30 seconds) means that hemodynamic effects resolve rapidly upon cessation [17].

Bradykinin and anaphylactoid reactions: Bradykinin release has been implicated in anaphylactoid reactions occurring during hemodialysis with certain negatively charged dialysis membranes (AN69 membranes) in patients taking ACE inhibitors. The combination of contact activation-induced bradykinin generation and ACE inhibitor-mediated bradykinin potentiation can produce severe hypotension in this clinical setting [14].

11. Dosing in Research

Bradykinin is not administered as a therapeutic agent. It is used as a research and diagnostic tool:

• Bradykinin challenge testing: Intradermal injection of bradykinin (nanomolar to micromolar concentrations) is used in research settings to assess vascular permeability, pain thresholds, and axon reflex responses
• Iontophoretic delivery: Used in clinical research to study microvascular endothelial function and NO-dependent vasodilation

Approved bradykinin-pathway modulators:

• Icatibant (B2 antagonist): 30 mg subcutaneous injection for acute HAE attacks; may repeat at 6-hour intervals, maximum 3 doses per 24 hours
• Lanadelumab (anti-kallikrein mAb): 300 mg subcutaneously every 2 weeks for HAE prophylaxis (may extend to every 4 weeks)
• Berotralstat (oral kallikrein inhibitor): 150 mg orally once daily for HAE prophylaxis

12. Related Peptides

See also: Angiotensin-(1-7), Substance P, VIP (Vasoactive Intestinal Peptide), Endothelin-1

13. References

1. [1] Rocha e Silva M, Beraldo WT, Rosenfeld G. (1949). Bradykinin, a hypotensive and smooth muscle stimulating factor released from plasma globulin by snake venoms and by trypsin. American Journal of Physiology. DOI PubMed
2. [2] Bhoola KD, Figueroa CD, Worthy K. (1992). Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacological Reviews. PubMed
3. [3] Marceau F, Regoli D. (2004). Bradykinin receptor ligands: therapeutic perspectives. Nature Reviews Drug Discovery. DOI PubMed
4. [4] Leeb-Lundberg LM, Marceau F, Muller-Esterl W, Pettibone DJ, Zuraw BL. (2005). International Union of Pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacological Reviews. DOI PubMed
5. [5] Yin W, Zhang P, Huang JH, Zhang QY, Fan R, Li J, et al. (2022). Cryo-EM structures of human bradykinin receptor-Gq proteins complexes. Nature Communications. DOI PubMed
6. [6] Dray A, Perkins M. (1993). Bradykinin and inflammatory pain. Trends in Neurosciences. DOI PubMed
7. [7] Couture R, Harrisson M, Vianna RM, Bhatt D. (2001). Kinin receptors in pain and inflammation. European Journal of Pharmacology. DOI PubMed
8. [8] Cicardi M, Banerji A, Bracho F, Malbran A, Rosenkranz B, Riedl M, et al. (2010). Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. New England Journal of Medicine. DOI PubMed
9. [9] Banerji A, Riedl MA, Bernstein JA, Cicardi M, Longhurst HJ, Zuraw BL, et al. (2018). Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks (HELP study). JAMA. DOI PubMed
10. [10] Garvin MR, Alvarez C, Miller JI, Prates ET, Walker AM, Amos BK, et al. (2020). A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm. eLife. DOI PubMed
11. [11] Erdos EG, Sloane EM. (1962). An enzyme in human blood plasma that inactivates bradykinin and kallidins. Biochemical Pharmacology. DOI PubMed
12. [12] Tom B, de Vries R, Saxena PR, Danser AH. (2001). Bradykinin potentiation by angiotensin-(1-7) and ACE inhibitors correlates with ACE C- and N-domain blockade. Hypertension. DOI PubMed
13. [13] Ceconi C, Francolini G, Olivares A, Comini L, Bachetti T, Ferrari R. (2007). Angiotensin-converting enzyme (ACE) inhibitors have different selectivity for bradykinin binding sites of human somatic ACE. European Journal of Pharmacology. DOI PubMed
14. [14] Bas M, Adams V, Suvorava T, Niehues T, Hoffmann TK, Kojda G. (2007). Nonallergic angioedema: role of bradykinin. Allergy. DOI PubMed
15. [15] Mukoyama M, Nakao K, Hosoda K, Suga S, Saito Y, Ogawa Y, et al. (2019). A review of the role of bradykinin and nitric oxide in the cardioprotective action of angiotensin-converting enzyme inhibitors. American Journal of Cardiovascular Drugs. DOI PubMed
16. [16] Dicpinigaitis PV. (2006). Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines. Chest. DOI PubMed
17. [17] Rhaleb NE, Yang XP, Carretero OA. (2011). The kallikrein-kinin system as a regulator of cardiovascular and renal function. Comprehensive Physiology. DOI PubMed
18. [18] Regoli D, Barabe J. (1980). Pharmacology of bradykinin and related kinins. Pharmacological Reviews. PubMed
19. [19] Qadri F, Bhatt D. (2021). Molecular basis for kinin selectivity and activation of the human bradykinin receptors. Nature Structural and Molecular Biology. DOI PubMed
20. [20] Schmaier AH. (2016). The contact activation and kallikrein/kinin systems: pathophysiologic and physiologic activities. Journal of Thrombosis and Haemostasis. DOI PubMed
21. [21] van de Veerdonk FL, Netea MG, van Deuren M, van der Meer JW, de Mast Q, Bruggemann RJ, et al. (2020). Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome. eLife. DOI PubMed
22. [22] Bader M. (2009). Kallikrein-kinin system in neovascularization. Arteriosclerosis, Thrombosis, and Vascular Biology. DOI PubMed
23. [23] Cole SW, Lundquist LM. (2013). Icatibant for the treatment of hereditary angioedema. Annals of Pharmacotherapy. DOI PubMed
24. [24] Liu J, Li H, Bhatt D. (2023). Pathophysiology of bradykinin and histamine mediated angioedema. Frontiers in Allergy. DOI PubMed
25. [25] Kaplan AP, Joseph K. (2002). Pathways for bradykinin formation and inflammatory disease. Journal of Allergy and Clinical Immunology. DOI PubMed